Covidien (NYSE:COV) revealed today in a regulatory filing that the U.S. Health & Human Services Dept. hit it with a subpoena for documents related to some of its devices for treating peripheral artery disease.
The Sept. 2 subpoena from the HHS inspector general’s office requested "documents relating to certain of our peripheral vascular products," according to a regulatory filing.
Mansfield, Mass.-based Covidien said it’s "complying as required" with the terms of the subpoena.
A Covidien spokesman declined to elaborate on which devices were named in the subpoena or what possible infractions the human services bureau is investigating.
Covidien is nearing the finish line on a blockbuster, $43 billion merger with Medtronic (NYSE:MDT) that would supplant Johnson & Johnson (NYSE:JNJ) as the world’s largest medical device business. The deal is expected to close early next year.